Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Ohio State University, Columbus, OH, USA.
Expert Opin Biol Ther. 2021 Jul;21(7):875-887. doi: 10.1080/14712598.2020.1776253. Epub 2020 Jun 8.
Ovarian cancer typically presents at an advanced stage and while initial chemotherapy response rates are favorable, a majority of patients experience recurrence with the subsequent development of chemoresistance. Recurrent, platinum-resistant disease is associated with a very poor prognosis as treatment in this setting is often limited by systemic toxicity. Antibody-drug conjugates (ADCs) are novel therapeutic agents designed to target antigens specific to ovarian tumor cells with direct delivery of cytotoxic agents to combat recurrent, platinum-resistant disease while limiting systemic toxicity.
The basic structure and function of ADCs will be reviewed as well as the current data on ADCs under investigation in ovarian cancer.
ADCs represent a promising class of targeted therapy in recurrent ovarian cancer with excellent response rates particularly when utilized as combination therapy. While mirvetuximab soravtansine is the only ADC that has been evaluated in a phase 3 trial, many other ADCs and trials are on the horizon. As the field of targeted therapy continues to evolve, continued development of target antigens and ADCs are likely to represent a key development in treatment of recurrent, platinum-resistant disease.
卵巢癌通常在晚期出现，虽然初始化疗反应率较好，但大多数患者会复发，并随后产生耐药性。复发性、铂耐药疾病的预后非常差，因为在这种情况下的治疗通常受到全身毒性的限制。抗体药物偶联物 (ADC) 是一种新型治疗剂，旨在针对卵巢肿瘤细胞特有的抗原，直接输送细胞毒性药物来对抗复发性、铂耐药疾病，同时限制全身毒性。
将回顾 ADC 的基本结构和功能，以及正在研究的卵巢癌 ADC 的最新数据。
ADC 代表了复发性卵巢癌靶向治疗的一个有前途的类别，特别是当作为联合治疗时，具有极好的反应率。虽然 mirvetuximab soravtansine 是唯一一种在 3 期试验中评估的 ADC，但许多其他 ADC 和试验正在进行中。随着靶向治疗领域的不断发展，针对抗原和 ADC 的持续开发可能是治疗复发性、铂耐药疾病的关键发展。
